|
|
||||||||
Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, and Department of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada R2H 2A6
| |
ABSTRACT |
|---|
|
|
|---|
Alterations in general
characteristics and morphology of the heart, as well as changes
in hemodynamics, myosin heavy chain isoforms, and
-adrenoceptor
responsiveness, were determined in Sprague-Dawley rats at 1, 2, 4, 8, and 16 wk after aortocaval fistula (shunt) was induced by the needle
technique. Three stages of cardiac hypertrophy due to volume
overload were recognized during the 16-wk period. Developing
hypertrophy occurred within the first 2 wk after aortocaval shunt was
induced and was characterized by a rapid increase of cardiac mass in
both left and right ventricles. Compensated hypertrophy occurred
between 2 and 8 wk after aortocaval shunt where normal or mild
depression in hemodynamic function was observed. Decompensated
hypertrophy or heart failure occurred between 8 and 16 wk after
aortocaval shunt and was characterized by circulatory congestion,
decreased in vivo and in vitro cardiac function, and a shift in myosin
heavy chain isozyme expression. However, the positive inotropic effect
of isoproterenol was augmented at all times during the 16-wk period.
Characterization of
-adrenoceptor binding in failing hearts at 16 wk
revealed a significant increase in
1-receptor density,
whereas
2-receptor density was unchanged. Consistent
with this, basal adenylyl cyclase activity was significantly increased,
and both isoproterenol- and forskolin-stimulated adenylyl cyclase
activities were also increased. These results indicate that
upregulation of
-adrenoceptor signal transduction is a unique feature of cardiac hypertrophy and failure induced by volume overload.
aortocaval fistula;
-adrenergic mechanisms
| |
INTRODUCTION |
|---|
|
|
|---|
CARDIAC HYPERTROPHY IS AN adaptive response of the heart to hemodynamic overload, during which terminally differentiated cardiomyocytes increase in size without undergoing cell division. Initially, the hypertrophic response may serve to compensate cardiac function; however, prolonged hypertrophy can become detrimental, resulting in cardiac dysfunction and heart failure (19, 23). Arteriovenous (AV) shunt or fistula (1, 13, 14, 16, 20, 21, 27, 28) has long been used as a model for inducing volume overload similar to that seen in conditions such as hyperthyroidism, anemia, and bundle branch block. However, changes in cardiac hypertrophy and hemodynamic parameters due to AV shunt are quite variable. Increase of cardiac mass has been reported to range from 20 to 100% (13, 16, 27, 28, 31), whereas cardiac contractility was increased (16), decreased (2, 34), or unchanged (27, 28). Circulatory congestion was also reported to be absent (6) or present (34). Such conflicting observations may be due to differences in the techniques utilized to induce volume overload or the stage of cardiac hypertrophy. Conventionally, AV fistula in rats is created by side-to-side anastomosis of the aorta and the vena cava (13) or by end-to-side anastomosis of the left iliolumbar vein (27). Both procedures require microvascular surgery, and the circulatory system had to be obstructed for 15-30 min (13, 27). Furthermore, because these surgical procedures require ~40 min to complete, the mortality was as high as 47-76% (13, 27). In addition, the shunt size as well as the hypertrophic and hemodynamic characteristics were inconsistent (13, 27).
Garcia and Diebold (15) described a simple, rapid, and effective method in which a needle (18 gauge) was used for making a shunt between the abdominal aorta and the inferior vena cava. The puncture site was then sealed with a drop of cyanoacrylate glue. The circulation was only occluded for 1-2 min, and the entire procedure was finished within 10 min; the mortality was under 10% (15). Subsequently, Huang et al. (22) evaluated the needle technique by using three different sizes of needle and confirmed that this technique can control the size of the shunt and provide consistent changes in hypertrophic growth and hemodynamic changes.
Several investigators have employed the volume overload model for
studying different aspects of cardiac remodeling, including changes in
the renin angiotensin system (41), extracellular matrix
(7, 11, 32, 40), and vitro cardiac contractility (6). Some studies have shown increased cardiac output and
cardiac index due to volume overload (22, 27, 38, 41).
Most of these studies were carried during 10 wk after the surgery when the signs of overt heart failure were not obvious; however, Brower and
Janicki (7) have characterized changes in the in vitro cardiac contractility at 21 wk after the surgery and reported that
heart failure due to volume overload may be associated with a
depression of the intrinsic cardiac function. The present study was
undertaken to investigate the time course changes in both in vivo and
in vitro hemodynamics during the development of cardiac hypertrophy due
to volume overload induced by the needle technique in rats.
Furthermore, it was planned to carry out experiments to examine
biochemical markers of heart dysfunction such as myosin isozyme
composition and the status of
-adrenergic system in this model of
cardiac hypertrophy.
| |
METHODS |
|---|
|
|
|---|
Preparation of the animal model. Experiments were conducted in accordance with the Guide to the Care and Use of Experimental Animals issued by the Canadian Council on Animal Care. Male Sprague-Dawley rats weighing 250-300 g were kept in a temperature-controlled room with a 6:00 AM to 6:00 PM light-dark cycle. Tap water and rat chow were provided ad libitum. The aortocaval shunt was produced according to the method described by Garcia and Diebold (15) with some modifications. Briefly, after the animal was anesthetized with isofluorane, a ventral abdominal laparotomy was performed. The intestines were displaced laterally and wrapped with normal saline-soaked sterilized gauze to retain moisture. The aorta and vena cava between the levels of renal arteries and iliac bifurcation were then exposed by blunt dissection of the overlaying adventitia. Both vessels were temporarily occluded proximal and distal to the intended puncture site, and a needle (18 gauge) held on a plastic syringe was inserted into the exposed abdominal aorta and advanced through the medial wall into the vena cava to create the shunt. The needle was inserted and withdrawn across the medial wall several times through the same hole, to ensure the size and presence of the shunt, before it was finally withdrawn from the aorta. The ventral aortic puncture site was immediately sealed with a drop of cyanoacrylate (Krazy Glue, Elmer's Product Canada, Brampton, ON) after withdrawal of the needle. Creation of a successful shunt was visualized by the pulsatile flow of oxygenated blood into the vena cava from the abdominal aorta. The intestines were repositioned, and the abdominal musculature and skin incisions were closed by standard techniques with absorbable suture and autoclips. Sham-operated animals serving as controls were subjected to the same surgical procedures except for creation of the shunt. During the whole process, the animal was ventilated by positive-pressure inhalation of 95% O2 and 5% CO2 mixed with isofluorane, as recommended by the University Animal Care Committee.
General characteristics. For determination of general characteristics, rats were weighed and then anesthetized by a mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg). The heart was removed and immediately placed in ice-cold saline to wash out the blood. Total heart, right ventricular (RV), and left ventricular (LV) weight were measured after the removal of connective tissue; the septum was included in the LV. The lung and liver were also taken out, and their wet weight was assessed. Both lung and liver tissues (~0.5 g each) were dried at 70°C for 3 days. To make sure that constant weight was achieved, tissue was weighed daily until no further weight loss could be detected. Dry-to-wet weight ratios (dry/wet weight) for these tissues were then calculated. Gross morphology of the heart was determined at 4, 8, and 16 wk after surgery. The hearts from sham and experimental groups were taken out, washed, and fixed in formalin buffer for 1 wk. The hearts were then blotted dry and sagitally cut to show the size of the cavity and thickness of the LV and RV walls as well as that of the septum.
Hemodynamic studies in vivo.
In vivo cardiac performance and arterial hemodynamics were measured via
a carotid artery catheter at 1, 2, 4, 8, and 16 wk after the induction
of aortocaval shunt. Rats were anesthetized with an intraperitoneal
injection of ketamine and xylazine mixture. The right carotid artery
was dissected, and an ultraminiature catheter connected to a pressure
transducer (model SPR-249, Millar Instruments, Houston, TX) was
inserted into the right carotid artery and then advanced into the LV.
The LV systolic pressure (LVSP), LV end-diastolic pressure (LVEDP),
heart rate, maximum rate of pressure development (+dP/dt),
and maximum rate of pressure decay (
dP/dt) were recorded
and stored in a computer (Biopac System, Goleta, CA). The catheter was
subsequently withdrawn to the aorta, and the arterial systolic pressure
(ASP) and arterial diastolic pressure (ADP) were measured. The pulse
pressure (PP) was then calculated as the difference between ASP and
ADP; and the mean arterial pressure (MAP) was calculated as the sum of ADP and 1/3 PP.
Myosin heavy chain isozyme analysis. The composition of myosin heavy chain isozymes was determined by polyacrylamide gel electrophoresis in the presence of pyrophosphate (39). Portions of the LV and RV (~50 mg) were cut into small pieces and extracted for 15 min by gentle agitation at 0°C with three volumes (vol/wt) of 40 mM Na4P2O7 (pH 8.8, adjusted with HCl at 2°C), 1 mM 1,4-dithioerythritol, and 5 mM EGTA. After centrifugation at 2,000 g for 15 min, the supernatant was collected and diluted 1:10 (vol/vol) with ice-cold glycerol and immediately loaded on the gel. The gel contained 3.8% acrylamide and 0.12% N,N'-methylenebis-acrylamide. Electrophoresis buffer contained 20 mM Na4P2O7 (pH 8.8) and 10% glycerol (vol/vol). Electrophoresis was carried out at 2°C for ~16 h at a voltage gradient of 10 V/cm. Gels were stained with Coomassie brilliant blue R250 for 2 h and destained with 7% acetic acid by diffusion. Relative amounts of isozymes were derived from densitometric tracings by using 2202 ultrascan laser densitometer (LKB). The V1, V2, and V3 isozymes were quantitated by measuring peak heights, and the values were expressed as percentages of the total isozymes.
Isolated heart perfusion and contractile measurements.
In vitro contractile function was measured by using an isolated
perfused heart preparation as described elsewhere (45). Briefly, at 4, 8, and 16 wk after the induction of an aortocaval shunt,
the animals were anesthetized with a mixture of ketamine and xylazine.
After administration of heparin (1,000 units), the thorax was opened,
and the heart was removed and immediately placed into ice-cold saline.
The adherent connective tissue was removed, and the heart was perfused
in the Langendorff perfusion apparatus at a constant flow (10 ml/min)
with Krebs-Henseleit solution containing (in mmol/l) 120 NaCl, 4.74 KCl, 1.2 KH2PO4, 1.2 MgSO4 · 7H2O, 25 NaHCO3, 1.25 CaCl2, and 11 glucose. This
solution (pH 7.4) was continuously oxygenated with 95% O2
and 5% CO2 mixture and maintained at 37°C. It should be
mentioned that the constant flow in the experimental setting used in
this study generates 60-70 mmHg pressure. The atrioventricular
node conduction was surgically blocked, and the heart was paced at 300 beats/min by a square wave of 1.5-ms duration at twice the threshold
voltage throughout the experiments by using a Philips & Bird stimulator
(Richmond, VA). The LVDP as well as +dP/dt and
dP/dt were measured by using a transducer connected to a
latex balloon (Harvard Apparatus, St. Laurent, PQ), which was inserted
into the LV. The balloon was connected with a plastic tube to a syringe
filled with double-distilled water. The system was adjusted to make
sure no air bubbles were inside the balloon and the tube, water was
withdrawn from the balloon, and the deflated balloon was inserted into
the LV. Water was then injected slowly into the balloon to adjust the
initial LVEDP to 10 mmHg. The size of the balloon was adjusted so as to be appropriately sized for different stages of volume overload and
different experimental groups to ensure that they fit into the LV
cavity. It should be pointed out that the balloon itself may not
contribute to the pressure measured because it was not fully inflated.
All data were recorded and stored by using the Biopac Data Acquisition
System (Biopac System, Goleta, CA), with recording being started after
the heart was stabilized for 30 min. For studying the inotropic
responses of these hearts, isoproterenol (1 µM) was infused in the
perfusion stream just above the aorta, and corresponding changes in
contractile parameters (peak responses) were recorded.
Preparation of crude membranes.
Crude membranes were used for
-adrenergic receptor (
-AR) binding
experiments and the adenylyl cyclase (AC) activity assay (35). Briefly, the LV tissue was minced and then
homogenized in 50 mM Tris · HCl, pH 7.4 (15 ml/g
tissue), with a PT-3000 Polytron (Brinkman Instruments, Westbury, NY)
twice for 20 s each at a setting of 6. The resulting homogenate
was centrifuged at 1,000 g for 10 min, and the pellet was
discarded. The supernatant was centrifuged at 48,000 g for
20 min. The resulting pellet was resuspended and centrifuged twice in
the same buffer at the same speed, after which the final pellet was
resuspended in 50 mM Tris · HCl, pH 7.4, containing 25 mM sucrose and 0.1 mM PMSF and stored at
80°C for
further experiments.
Determination of
-AR binding.
Kinetic properties of
1- and
2-AR binding
were determined as described previously (35). Briefly, 100 µg of membranes were incubated in Tris · HCl
buffer (pH 7.4) for 60 min at 37°C with different concentrations
(6.25-400 pM) of [125I]iodo-cyanopindolol
([125I]ICYP) in the absence or presence of either 200 µM CGP-20712A (a highly selective
1-antagonist) or 10 µM ICI-118551 (a highly selective
2-antagonist). The reaction was terminated by
rapid vacuum filtration through Whatman GF/C filters, and the membranes were washed three times with 5 ml of cold water. The radioactivity was
counted in a Beckmann gamma counter. Specific binding to
1-receptors was calculated as the difference between
[125I]ICYP binding values in the absence and presence of
CGP-20712A, whereas
2-receptor-specific binding was the
difference between [125I]ICYP binding values in the
absence and presence of ICI-118551. The kinetic parameters, maximal
binding, and Kd were calculated from the
Schatchard plot analysis according to the interactive LIGAND program.
Determination of AC activity.
The AC activity was determined by measuring the formation of
[32P]cAMP from [
-32P]ATP as described
earlier (43). Unless otherwise indicated, the incubation
assay medium contained 50 mM glycylglycine (pH 7.5), 0.5 mM cAMP, 0.5 mM MgATP, 100 mM NaCl, 5 mM MgCl2, 0.1 mM EGTA, 0.5 mM
3-isobutyl-1-methylxanthine, 10 U/ml adenosine deaminase,
[32P]ATP (1-1.5 × 106), and an
ATP-regenerating system comprising 2 mM creatine phosphate, 0.1 mg/ml
creatine kinase, and 36 U/ml myokinase in a final volume of 200 µl.
The reaction was initiated by the addition of 40-60 µg of crude
membranes to the reaction mixture, which had been equilibrated for 3 min at 37°C. The incubation time was 10 min at 37°C, and the
reaction was terminated by the addition of 0.6 ml of 120 mM zinc
acetate containing 0.5 mM unlabeled cAMP. The [32P]cAMP
formed during the reaction was determined after precipitation with
ZnCO3 by the addition of 0.5 ml of 144 mM
Na2CO3 and subsequent chromatography by a
double-column system, as described earlier (43). The
unlabeled cAMP served to monitor the recovery of
[32P]cAMP by measuring absorbency at 259 nM; AC activity
was expressed as picomoles of cAMP per milligrams of protein per 10 min. The AC activity was linear with respect to protein concentration
and time of incubation under the assay conditions used. When G
protein-stimulated AC was estimated, 30 µM
5'-guanylylimidodiphosphate [Gpp(NH)p] or 10 mM NaF were added to the
reaction mixture; other experiments were carried out in the presence of
100 µM isoproterenol or 100 µM forskolin.
Statistics. All values were expressed as means ± SE. One-way ANOVA followed by unpaired Student's t-test was used for comparisons between sham control and experimental groups. Difference was considered significant at a level of P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
General characteristics of the AV shunt rat model. Of 60 rats that underwent AV shunt surgery, five (8.3%) died within 24-72 h after the operation. Necropsy examination failed to reveal bleeding from the puncture site or vascular obstruction. However, the hearts were markedly dilated, with the right atria, LV, and RV being greatly enlarged, suggesting that these animals died from their inability to compensate for the acute volume overload. Although no further mortality occurred between 1 and 8 wk after the operation, three rats (5%) died between 10 and 16 wk after the surgery. Necropsy examination of these rats demonstrated hypertrophied heart, congested liver and lung, presence of ascites and pleural effusion, as well as edema of the limbs, suggesting that these animals died of congestive heart failure. In addition, rats that survived for 16 wk after AV shunt surgery were sluggish in their movements, and the hair around their face and neck area was stained with blood, most probably due to bloody sputum as a consequence of lung congestion. The AV shunt rats killed at 16 wk demonstrated ascites. The sham control group showed no mortality during 16 wk after the operation.
The time course changes in the general characteristics in rats with and without AV shunt are shown in Table 1. Although there was no significant difference in body weight between the sham and AV shunt groups at each time interval, heart weight of the experimental group increased progressively during 1-16 wk. Accordingly, heart weight-to-body weight ratio was significantly increased at all time intervals. While examining LV and RV weight separately, we found that hypertrophy of the RV was greater than that of the LV (152, 193, and 249% of control for RV vs. 112, 147 and 188% of control for LV) at 1, 2, and 16 wk, respectively, after the aortocaval shunt. However, the extent of LV hypertrophy at 4 and 8 wk was similar to that of the RV (187 and 171% of control for RV vs. 181 and 171% of control for LV, respectively). No significant difference was found in heart rate between sham and AV shunt groups throughout the observation period; this is similar to the findings of other investigators (13, 21, 27, 28, 41).
|
Morphological changes and circulatory congestion.
The gross morphological changes in the heart are shown in Fig.
1. The left panel shows a
progressive enlargement of the heart from 4 to 16 wk in the AV shunt
group, whereas the right panel shows the dilation of the LV
and RV cavities and increase of wall thickness in the vertically cut
heart, indicating eccentric hypertrophy in this model. Our histology
studies (data not shown) confirmed the previous observation of Hatt et
al. (20) that, in the AV shunt group, the myocytes were
thickened and nuclei were enlarged. In contrast to Hatt et al.,
disarray of myofibrils was also seen in some hearts at 8 and 16 wk
after the AV shunt was induced.
|
|
In vivo cardiac performance and arterial hemodynamics.
The time course changes in cardiac performance under in vivo conditions
due to volume overload are shown in Fig.
2. Although a significant elevation of
LVEDP was detected throughout the 16-wk observation period (Fig.
2A), the changes were biphasic in nature. The first peak
occurred at 1 wk, and this elevation was then reduced somewhat at 2 and
4 wk, whereas it started to increase at 8 wk and reached another peak
at 16 wk. On the other hand, the LVSP was unaltered at 1, 2, and 4 wk
but was progressively decreased at 8 and 16 wk after the AV shunt (Fig.
2B). Similarly, no changes were detected for
+dP/dt and
dP/dt at 1, 2, and 4 wk after the surgery, but progressive depressions were seen at 8 and 16 wk (Fig. 2,
C and D). The results in Fig.
3 show the time course changes in
arterial hemodynamics on inducement of the AV fistula. Biphasic changes
in both ASP (Fig. 3A) and MAP (B) were detected; significant depressions were evident at earlier stages (1 and 2 wk) and
later stages (16 wk) without any significant alterations in between (4 and 8 wk) on inducement of the AV shunt. The ADP was significantly
lower in the AV shunt group compared with the sham group, although the
extent of decrease was milder at 4 and 8 wk compared with other time
points (Fig. 3C). The PP was significantly increased
throughout the 16-wk observation period, indicating the presence of AV
shunt in the experimental group (Fig. 3D).
|
|
Myosin isozyme composition.
In view of the critical role played by a shift in the composition of
myosin heavy chain isozymes in heart function in rodents (31), we examined the time course of changes in myosin
heavy chain isozyme composition in the AV shunt group. Figure
4, top, shows the positions of
V1, V2, and V3 on the gel
electrophoresis. The bottom panels show the time course
changes in the myosin heavy chain isozyme composition in both RV and LV
after the AV shunt was induced in rats. There was a slight
age-dependent increase in V3 in both LV and RV from sham
controls, which is similar to that observed by Mercadier et al.
(31). However, no significant shift of myosin heavy chain
V1 to V3 was detected in LV until 8 wk and in
RV until 16 wk. Table 3 shows the values
of V1, V2, and V3 (in percentage)
in RV and LV at 4, 8, and 16 wk after the AV shunt was induced; the
values at 1 and 2 wk were not shown because they were similar to those
at 4 wk. No change was detected in myosin heavy chain isoform
expression between the 4-wk sham and AV groups. On the other hand, a
progressive decrease in V1 and an increase in
V3 were apparent in the LV from the 8- and 16-wk AV shunt
groups. In contrast to the changes in the LV, it was interesting to
observe that no significant change in the composition of myosin heavy
chain isozymes was evident in the RV from the 1- to 8-wk AV shunt
animals (Table 3).
|
|
In vitro contractile function and response to isoproterenol.
Because in vivo performance of the heart is largely influenced by a
number of neurohormonal factors and peripheral hemodynamic changes, we
measured the LV contractile function in the isolated perfused heart to
determine whether an intrinsic cardiac dysfunction was present in the
heart of AV-shunted rat. Figure 5 shows
that LVDP, +dP/dt, and
dP/dt were significantly
decreased at 4, 8, and 16 wk after the AV shunt. Compared with the in
vivo hemodynamic parameters, the LV contractile dysfunction in vitro
occurred earlier (4 vs. 8 wk) and was more dramatic (75, 63, and 48%
of sham vs. 94, 82, and 64% of sham for +dP/dt; and 82, 60, and 50% of sham vs. 94, 79, and 61% of sham for
dP/dt at
4, 8, and 16 wk, respectively), indicating the effect of compensatory
mechanisms under in vivo conditions. The in vitro cardiac performance
of hearts from the 1- and 2-wk AV shunt group was not different from
that of the sham control group (data not shown).
|
Assessment of
-AR system.
Because the inotropic response of isolated heart to isoproterenol
stimulation was not attenuated as in other types of heart failure
(9, 46), we examined this aspect under in vivo conditions at 16 wk in AV-shunted rats. As shown in Table
4, a bolus injection of isoproterenol
stimulated the contractile function of sham and AV shunt groups to
similar levels, despite their difference in basal levels. This
indicated that the
-adrenergic system in this model is maintained or
upregulated. To find out the biochemical basis for this phenomenon, we
measured
-AR binding and AC activity in the LV in rats 16 wk after
inducing the AV shunt. The results in Table
5 indicate an increase in the receptor
density or maximum binding for
1-ARs but not
2-ARs. The receptor affinity, as reflected by
Kd, was not altered for either
1-
or
2-ARs, whereas the AC assay revealed a significant
increase in AC enzyme activity in both the absence (basal) and presence
of isoproterenol, Gpp(NH)p, NaF, and forskolin due to volume overload
(Fig. 6A). When the data were
expressed as stimulation with respect to the corresponding basal
activities, only isoproterenol- and forskolin-stimulated AC
activities were increased, whereas Gpp(NH)p- and NaF-stimulated enzyme
activities were unaltered in the AV-shunted hearts (Fig. 6B).
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
First, it should be pointed out that the aortocaval shunt in rats,
as employed in this study, is by no means a new model of volume
overload, because there exists literature characterizing the aortocaval
fistula model from different aspects (1, 13, 14, 16, 20, 21, 27,
28). However, the needle technique (15, 22, 41)
used in this study is a breakthrough for inducing the volume overload.
Previously, the fistula was produced by side-to-side or end-to-side
anastomosis of vessels, which not only caused severe trauma to the
animal but also induced variable shunt sizes in the surviving animals.
Furthermore, flow through the fistula was constricted due to the
remodeling of the vessel wall after the injury due to operation, and
thus the data collected from the surviving animals did not reflect only
the volume overload but also the pressure overload. Due to these
limitations, the occurrence of hypertrophy and heart failure, as well
as changes in hemodynamic function, were not consistent in this volume
overload model (1, 13, 14, 16, 20, 21, 27, 28). On the
other hand, with the needle technique, the injury due to operation is
minimized, and the shunt size can be controlled by using different
sizes of needles (6, 7, 8, 11, 15, 22, 40, 41). In this
study, we have presented several novel findings, including the time
course changes in myosin heavy chain isoform composition, enhanced
responses to isoproterenol, increased
1-AR density, and
increased AC activity due to volume overload. Furthermore, our data
concerning morphometric and hemodynamic characterization of developing,
compensated, and decompensated cardiac hypertrophy can serve as a basis
of future investigations seeking to identify metabolic, subcellular,
and molecular defects in heart dysfunction due to volume overload. In
fact, the time course changes in this study suggest that the
development of cardiac hypertrophy and heart failure in this model is
consistent with three stages of cardiac remodeling: namely, developing
hypertrophy, compensated hypertrophy, and decompensated hypertrophy or
heart failure as defined by Meerson (30).
Changes in cardiac mass. We have demonstrated a progressive increase in cardiac mass; this is in agreement with the observations of others who have employed the same needle technique for creating the aortocaval shunt (6, 7, 8, 11, 22, 40, 41). It should be mentioned that there are several features unique to the cardiac hypertrophic growth induced by aortocaval shunt. First, during the 16-wk period evaluated, the increase of cardiac mass occurred in two bursts. The initial burst occurred over the first 2 wk after the operation (17 and 39% greater than control at 1 and 2 wk, respectively) and then slowed down at 4 wk (21%), and by 8 wk the rate of cardiac growth was comparable to that in the sham group. The other burst occurred between 8 and 16 wk, during which the cardiac muscle mass grew from 11 to 32% in the AV shunt group. These dynamic changes in growth rate after the aortocaval shunt correlate with the acute-response, compensated, and decompensated phases of the disease. The second feature is that the gain in the RV weight was more than that in the LV. This may be due to the different hemodynamic challenges that the LV and RV face on inducement of the AV shunt. By using radioactive microsphere techniques, some studies have shown dramatically increased cardiac output after inducing an AV shunt (14, 21, 27), with as much as 75% of the cardiac output being shunted through the fistula (22). In addition, pulmonary hypertension has long been recognized as a consequence of AV fistula in dogs and humans (12, 18). Accordingly, the RV can be seen to be under the challenge of both volume and pressure overload, thus exhibiting a more rapid and greater hypertrophic response. The more extensive hypertrophy response of the RV compared with that of the LV has also been observed by other investigators (27, 28, 41). By measuring the length and width of isolated cardiomyocytes, Liu et al. (27, 28) found that the increase in RV cell volume at 1 wk was more prominent than that in the LV or the intraventricular septum (27). Similar findings were also reported at 1 and 5 mo after the AV fistula was created (28). Ruzicka et al. (41) also reported an increase of 40 and 76%, respectively, in LV and RV weight 4 wk after inducing an AV shunt. Finally, the extent of cardiac hypertrophy in the AV shunt group doubled at 16 wk compared with that of the sham control; this feature is comparable to that occurring in human hypertrophic hearts (3, 4), whereas the extent of cardiac hypertrophy in most other types of experimental models in rodents does not attain this level (10, 19, 25).
In vivo and in vitro hemodynamic changes. Our in vivo hemodynamic data suggest a sustained elevation of LVEDP during the 1- to 16-wk period; however, discrepancies exist with respect to the time course changes. Brower et al. (6) showed a peak increase in LVEDP at 3 wk postsurgery and gradual decline at 5 and 8 wk. In their recent study with 21-wk observation after the aortocaval shunt, the LVEDP-LV end-diastolic volume curve, an index of diastolic function, was not different among 8, 15, and 21 wk postsurgery, suggesting no further deterioration of LV diastolic function in their animals. Ruzicka et al. (41) showed a peak elevation of LVEDP in the first week and, thereafter, a gradual decrease by 4 and 7 wk. Our data are similar to the latter because we found a dramatic increase in LVEDP at 1 wk after the surgery. This change reflects the sudden increase of wall stress due to the volume overload after the AV shunt was opened, whereas the significant reduction in LVEDP from 1 to 2 wk indicates that the developing cardiac hypertrophy and dilation of the cardiac chamber tend to normalize the wall stress. In fact, Dolgilevich et al. (11) have demonstrated by echocardiography that one-half of the LV dilation occurred in the first week after surgery. This structural remodeling induced by the AV shunt forms the basis for the decline in LVEDP at 2 wk. By 4 wk postsurgery, LVEDP reached the lowest level, indicating the maximum compensation at this time point. Furthermore, the increase in LVEDP at 8 and 16 wk is in contrast to that observed by Brower and Janicki (7); however, this further deterioration of the diastolic function is consistent with further LV dilation, decreased systolic function, increased myocardial stiffness, and occurrence of heart failure due to prolonged volume overload.
Several studies have shown increased cardiac output and decreased total peripheral resistance in the AV-shunted rats (22, 27, 41). In view of the unchanged heart rate after the aortocaval shunt, it appears that the maintenance of high-output status at early stages relies on the Frank-Starling reserve and the intact contractile function. In this regard, we have observed that the in vivo LV function was maintained at 4 wk and was only reduced by ~20% at 8 wk after the AV shunt was induced. However, Ruzicka et al. (41) showed a decrease in LV systolic function, despite an increase in cardiac index, and argued that the decreased total peripheral resistance might account for the large increase in stroke volume. On the other hand, Huang et al. (22) showed that the cardiac index was more than three times higher than that of control at 5 wk after aortocaval fistula. It is also possible that the maintained LV systolic function may contribute toward the dramatic elevation of cardiac output at this stage. Our data concerning changes in arterial hemodynamics during 16 wk after the AV shunt was induced reveal that the PP was increased throughout the observation period; this indicated the patency of the shunt. The MAP was slightly decreased in the early stage at 1 and 2 wk, normalized at 4 and 8 wk, and decreased again at 16 wk. Whereas Huang et al. reported normal MAP at 5 wk in the aortocaval shunt model, both Ruzicka et al. (41) and Liu et al. (27, 28) reported that MAP was decreased throughout the experimental period. Our data are consistent with these previous reports in that there was an overall decrease in MAP in the AV shunt groups, although the decrease at 4 and 8 wk did not attain statistical significance. Such variations in the temporal course are due to differing methodologies for creating the shunt. It should also be pointed out that our data reflect a slight decrease in ASP but no change in LVSP at 1 and 2 wk; this discrepancy may be due to the dramatic decrease in total peripheral resistance as the blood flow is immediately shunted to the vena cava, thus causing a slight decrease in ASP. The difference from our in vivo and in vitro hemodynamic data suggests in vivo compensation by neurohumoral mechanisms, such as the sympathetic nervous system and the renin-angiotensin system. In this regard, Communal et al. (8) have reported a decrease in catecholamine concentration in the ventricle without any change in plasma levels 4 wk after inducing an aortocaval shunt in rat. Although Ruzicka et al. (41) have reported an increase in the levels of plasma and cardiac renin activities, angiotensin II concentrations in plasma and ventricles were not determined. In view of the fact that the shunt is produced infrarenal and the blood flow to both sides of the kidney was not reduced (22) on creation of the aortocaval shunt, the activation of the renin-angiotensin system may be minimal in this experimental model until the occurrence of cardiac decompensation. Alternatively, an increase in myocardial sensitivity to in vivo circulating hormones or local neurotransmitter may occur to compensate for contractile function at early stages of cardiac hypertrophy due to volume overload.Myosin isozyme composition. Myosin heavy chain isozyme composition has long been known as an indicator of changes in myosin Ca2+-ATPase and myocardial contractility (37, 42) in rodents. It should be pointed out that V1 myosin heavy chain exhibits high Ca2+-ATPase activity and fast velocity of contraction, whereas V3 myosin heavy chain has low Ca2+-ATPase activity and slow velocity of contraction (37, 42). A correlation of cardiac hypertrophy and myosin heavy chain isozyme shift from V1 to V3 has been obtained from several hemodynamic overload models (24, 31). However, our results indicate that a shift in myosin heavy chain isozyme expression occurred in the decompensated hypertrophic stage after the AV shunt when the heart weight was doubled compared with the control. Although significant hypertrophy was present at earlier stages, V3 myosin heavy chain expression was not increased. This is consistent with the findings of Mercadier et al. (31), who found that increased expression of the V3 myosin heavy chain isozyme was not correlated significantly with the extent of cardiac hypertrophy in rats with AV fistula, whereas a good relationship between V3 expression and cardiac hypertrophy was observed in the aortic stenosis and aortic insufficiency models. Our results also demonstrate a difference in the time course of the V3 shift between LV and RV. Theoretically, this shift should occur earlier in the RV because rapid and more prominent hypertrophy was observed in this ventricle compared with the LV. On the contrary, the myosin isozyme shift occurred in the LV at 8 wk, whereas such a change was only observed at 16 wk in the RV. The probability is that the delayed appearance of myosin isozyme shift in the RV reflects progressive LV decompensation, which then imposes even greater workload on the RV, resulting in the development of RV decompensation. Nevertheless, our results indicate that one of the molecular mechanisms for the observed contractile dysfunction may be related to the alteration of myosin heavy chain isozyme composition, because the time course of myosin heavy chain isozyme shift from V1 to V3 in the LV corresponded to the changes in LV function under in vivo conditions.
Occurrence of heart failure. Chronic heart failure is easily detected in human with an AV fistula (5, 17, 44), as well as in large animals with aortocaval shunt (1, 34). However, occurrence of heart failure in the rat aortocaval shunt model is rather controversial. For example, Liu et al. (28) demonstrated no contractile dysfunction 5 mo after inducing a large shunt by end-to-side anastomosis of the left iliolumber vein and aorta in rats. By using left ventriculography to evaluate cardiac function, Yang et al. (47) also reported that cardiac dysfunction was minimal in rat with AV shunt 12 wk after the surgery. In contrast, by studying the pressure-volume relationship, Brower et al. (6) demonstrated a decrease in intrinsic contractility at 1, 3, 5, and 8 wk after inducing the AV shunt, but the number of rats progressed to clinical overt heart failure was <3% during the 8-wk observation period. However, when these investigators (7) extended their studies for a prolonged period and used different approaches to measure the morbidity and mortality, they were able to show 80% incidence of heart failure after 21 wk of chronic volume overload. It seems that the variation in the occurrence of heart failure among different studies may be related to differences in techniques applied for producing the shunt, magnitude, and duration of the volume overload and approaches to measure the signs of heart failure. Nevertheless, our data are in agreement with those of Brower and Janicki (7), namely that heart failure occurred in rats with chronic volume overload produced by the AV shunt. In addition to dramatic changes in LV mass, diastolic and systolic dysfunction, as well as biochemical alterations, there were signs of circulatory congestion and mortality during 8-16 wk after the AV shunt. As reported by Brower and Janicki, the lung wet weight was significantly increased; however, the lung dry/wet weight was not increased because the dry weight was also increased proportionally. Histological examination indicated that the pulmonary interstitial septa were thickened in the lungs of the chronic AV shunt groups. This suggests that the increased lung wet weight may be due to both edema and organic changes, which may occur in the lung after chronic pulmonary overloading. Consistent with the development of pulmonary edema, liver wet weight was also significantly increased with a corresponding decrease in the dry/wet weight after 8-16 wk of the volume overload. Histology studies revealed distended central veins and fibrosis of the vessel wall in the liver, suggesting long-term congestion in the liver. Furthermore, there was a mortality of 5% due to heart failure in the later stage of the AV shunt; these values were comparable to those reported by Brower and Janicki (7). Taken together, we believe that congestive heart failure occurs in rats after a prolonged period of volume overload.
Upregulation of
-adrenergic system.
One unique feature of this volume overload model is that, although the
failing stage was achieved at 16 wk after the AV shunt was induced, the
positive inotropic response of the heart to isoproterenol was not
depressed. In fact, the stimulatory effect of isoproterenol was
increased in the isolated heart at 4, 8, and 16 wk of inducing the AV
shunt. In vivo response to isoproterenol was also maintained at 16 wk
postsurgery. This observation is in contrast to several reports
showing attenuated responses of hypertrophied failing hearts to
catecholamines (see Refs. 9 and 46 for
reviews). However, we have also observed an upregulation of
1-receptor density and increased AC activity in the
AV-shunted hearts, in contrast to several studies that found
downregulation of both
-ARs after in vivo infusion of isoproterenol
in rats (29, 33). Because chronic
-blockade in vivo is
known to upregulate the
-ARs density (26, 36), it is
possible that upregulation of
1-ARs observed in the
aortocaval shunt model is related to decreased stimulation of the
sympathetic nervous system. In fact, Communal et al. (8)
demonstrated a decreased concentration of catecholamines in the
ventricle without any change in plasma levels in rats 4 wk after
inducing aortocaval shunt in rat. Thus the upregulation of
1-ARs without a change in
2-AR may
be associated with a decrease in neuronally released norepinephrine
from the AV-shunted hearts. In addition, our results showed increased
AC activities in basal, isoproterenol-, Gpp(NH)p-, NaF-, as well
as forskolin-stimulated AC in both LV and RV 16 wk after the AV shunt
was induced. It is pointed out that isoproterenol is known to activate
AC through the
-ARs, whereas Gpp(NH)p and NaF activate AC through
Gs proteins and forskolin exerts its stimulatory effect by
interacting with the catalytic unit of AC directly (9,
46). Because AC activity was increased under basal and all
stimulatory conditions, it is hard to assess the individual
contribution of
-ARs, G protein, and AC to this phenomenon. However,
when the data were expressed in terms of the stimulation with respect
to basal enzyme activity, the results indicated that isoproterenol and
forskolin induced greater activation of AC in the AV shunt group,
whereas the extent of stimulation due to Gpp(NH)p or NaF was similar
between the sham and experimental groups. This pattern of enhanced
signals at the receptor and effector levels is consistent with
increased
1-receptor density and increased basal
activity of AC in the failing hearts due to AV shunt. Furthermore,
upregulation of AC in the RV and downregulation of AC in the viable LV
have been reported to occur during the development of heart failure due to myocardial infarction (43).
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by a grant from the Heart and Stroke Foundation of Manitoba. N. S. Dhalla holds the Canadian Institutes of Health Research/Pharmaceutical Research and Development Chair in Cardiovascular Research supported by Merck Frosst, Canada. X. Wang and E. Sentex were supported by a Studentship and a Postdoctoral Fellowship, respectively, from the Heart and Stroke Foundation of Canada.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: N. S. Dhalla, Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, 351 Tache Ave., Winnipeg, MB, Canada R2H 2A6 (E-mail: cvso{at}sbrc.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/japplphysiol.00248.2002
Received 25 March 2002; accepted in final form 30 September 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Alyono, D,
Ring WS,
Anderson MR,
and
Anderson RW.
Left ventricular adaptation to volume overload from large aortocaval fistula.
Surgery
96:
360-367,
1984[Web of Science][Medline].
2.
Alyono, D,
Ring WS,
Crumbley AJ,
Schneider JR,
O'Connor MJ,
Parrish D,
Bache RJ,
and
Anderson RW.
Global left ventricular contractility in three models of hypertrophy evaluated with Emax.
J Surg Res
37:
48-54,
1984[Web of Science][Medline].
3.
Astorri, E,
Bolognesi R,
Colla B,
Chizzola A,
and
Visioli O.
Left ventricular hypertrophy: a cytometric study on 42 human hearts.
J Mol Cell Cardiol
9:
763-775,
1977[Web of Science][Medline].
4.
Astorri, E,
Chizzola A,
Visioli O,
Anversa P,
Olivetti G,
and
Vitali-Mazza L.
Right ventricular hypertrophy
a cytometric study on 55 human hearts.
J Mol Cell Cardiol
2:
99-110,
1971[Web of Science][Medline].
5.
Brewster, DC,
Cambria RP,
Moncure AC,
Darling RC,
LaMuraglia GM,
Geller SC,
and
Abbott WM.
Aortocaval and iliac arteriovenous fistulas: recognition and treatment.
J Vasc Surg
13:
253-264,
1991[Web of Science][Medline].
6.
Brower, GL,
Henegar JR,
and
Janicki JS.
Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload.
Am J Physiol Heart Circ Physiol
271:
H2071-H2078,
1996
7.
Brower, GL,
and
Janicki JS.
Contribution of ventricular remodeling to pathogenesis of heart failure in rats.
Am J Physiol Heart Circ Physiol
280:
H674-H683,
2001
8.
Communal, C,
Ribuot C,
Durand A,
and
Demenge P.
Myocardial
-adrenergic reactivity in volume overload induced cardiac hypertrophy in the rat.
Fundam Clin Pharmacol
12:
411-419,
1998[Web of Science][Medline].
9.
Dhalla, NS,
Wang X,
Sethi R,
Das PK,
and
Beamish RE.
-Adrenergic linked signal transduction mechanisms in failing heart.
Heart Failure Reviews
2:
55-65,
1997.
10.
Doering, CW,
Jalil JE,
Janicki JS,
Pick R,
Aghili S,
Abrahams C,
and
Weber KT.
Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy.
Cardiovasc Res
22:
686-695,
1988[Web of Science][Medline].
11.
Dolgilevich, SM,
Siri FM,
Atlas SA,
and
Eng C.
Changes in collagen and collagen gene expression after induction of aortocaval fistula in rats.
Am J Physiol Heart Circ Physiol
281:
H207-H214,
2001
12.
Epstein, FH,
Shadle OW,
Ferguson TB,
and
McDowell ME.
Cardiac output and intracardiac pressures in patients with arteriovenous fistula.
J Clin Invest
32:
543-547,
1953[Web of Science][Medline].
13.
Flaim, SF,
Minteer WJ,
Nellis SH,
and
Clark DP.
Chronic arteriovenous shunt: evaluation of a model for heart failure in rat.
Am J Physiol Heart Circ Physiol
236:
H698-H704,
1979
14.
Flaim, SF,
Minteer WJ,
and
Zelis R.
Acute effects of arterio-venous shunt on cardiovascular hemodynamics in rat.
Pflügers Arch
385:
203-209,
1980[Web of Science][Medline].
15.
Garcia, R,
and
Diebold S.
Simple, rapid, and effective method of producing aortocaval shunts in the rat.
Cardiovasc Res
24:
430-432,
1990
16.
Gerdes, AM,
Clark LC,
and
Capasso JM.
Regression of cardiac hypertrophy after closing an aortocaval fistula in rats.
Am J Physiol Heart Circ Physiol
268:
H2345-H2351,
1995
17.
Ghilardi, G,
Scorza R,
Bortolani E,
de Monti M,
Longhi F,
and
Ruberti U.
Primary aortocaval fistula.
Cardiovasc Surg
2:
495-497,
1994[Medline].
18.
Gibbon, JH, Jr,
and
Churchill ED.
Changes in pulmonary circulation induced by experimentally produced arteriovenous fistula.
Arch Surg
21:
1184-1194,
1930.
19.
Hasenfuss, G.
Animal models of human cardiovascular disease, heart failure and hypertrophy.
Cardiovasc Res
39:
60-76,
1998
20.
Hatt, PY,
Rakusan K,
Gastineau P,
Laplace M,
and
Cluzeaud F.
Aorto-caval fistula in the rat. An experimental model of heart volume overloading.
Basic Res Cardiol
75:
105-108,
1980[Web of Science][Medline].
21.
Huang, M,
Hester RL,
and
Guyton AC.
Hemodynamic changes in rats after opening an arteriovenous fistula.
Am J Physiol Heart Circ Physiol
262:
H846-H851,
1992
22.
Huang, M,
LeBlanc MH,
and
Hester RL.
Evaluation of the needle technique for producing an arteriovenous fistula.
J Appl Physiol
77:
2907-2911,
1994
23.
Hunter, JJ,
and
Chien KR.
Signaling pathways for cardiac hypertrophy and failure.
N Engl J Med
341:
1276-1283,
1999
24.
Imamura, S,
Matsuoka R,
Hiratsuka E,
Kimura M,
Nakanishi T,
Nishikawa T,
Furutani Y,
and
Takao A.
Adaptational changes of MHC gene expression and isozyme transition in cardiac overloading.
Am J Physiol Heart Circ Physiol
260:
H73-H79,
1991
25.
Ju, H,
Zhao S,
Jassal DS,
and
Dixon IMC
Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction.
Cardiovasc Res
35:
223-232,
1997
26.
Karliner, JS.
Effects of
-blockade on
-adrenergic receptors and signal transduction.
J Cardiovasc Pharmacol
4, Suppl5:
S6-S12,
1989.
27.
Liu, Z,
Hilbelink DR,
Crockett WB,
and
Gerdes AM.
Regional changes in hemodynamics and cardiac myocyte size in rats with aortocaval fistulas. 1. Developing and established hypertrophy.
Circ Res
69:
52-58,
1991
28.
Liu, Z,
Hilbelink DR,
and
Gerdes AM.
Regional changes in hemodynamics and cardiac myocyte size in rats with aortocaval fistulas. 2. Long-term effects.
Circ Res
69:
59-65,
1991
29.
Lu, XY,
and
Barnett DB.
Differential rates of down regulation and recovery of rat myocardial
-adrenoceptor subtypes in vivo.
Eur J Pharmacol
182:
481-486,
1990[Web of Science][Medline].
30.
Meerson, FZ.
The myocardium in hyperfunction, hypertrophy and heart failure.
Circ Res
25, Suppl2:
1-163,
1969
31.
Mercadier, JJ,
Lompre AM,
Wisnewsky C,
Samuel JL,
Bercovici J,
Swynghedauw B,
and
Schwartz K.
Myosin isoenzyme changes in several models of rat cardiac hypertrophy.
Circ Res
49:
525-532,
1981
32.
Namba, T,
Tsutsui H,
Tagawa H,
Takahashi M,
Saito K,
Kozai T,
Usui M,
Imanaka-Yoshida K,
Imaizumi T,
and
Takeshita A.
Regulation of fibrillar collagen gene expression and protein accumulation in volume-overloaded cardiac hypertrophy.
Circulation
95:
2448-2454,
1997
33.
Nanoff, C,
Freissmuth M,
Tuisl E,
and
Schutz W.
A different desensitization pattern of cardiac
-adrenoceptor subtypes by prolonged in vivo infusion of isoprenaline.
J Cardiovasc Pharmacol
13:
198-203,
1989[Web of Science][Medline].
34.
Newman, WH,
Webb JG,
and
Privitera PJ.
Persistence of myocardial failure following removal of chronic volume overload.
Am J Physiol Heart Circ Physiol
243:
H876-H883,
1982
35.
Persad, S,
Takeda S,
Panagia V,
and
Dhalla NS.
-Adrenoreceptor-linked signal transduction in ischemic-reperfused heart and scavenging of oxyradicals.
J Mol Cell Cardiol
29:
545-558,
1997[Web of Science][Medline].
36.
Ping, P,
Gelzer BR,
Roth DA,
Kiel D,
Insel PA,
and
Hammond HK.
Reduced
-adrenergic receptor activation decreases G-protein expression by
-adrenergic receptor kinase activity in porcine heart.
J Clin Invest
95:
1271-1280,
1995[Web of Science][Medline].
37.
Pope, B,
Hoh JF,
and
Weeds A.
The ATPase activities of rat cardiac myosin isoenzymes.
FEBS Lett
118:
205-208,
1980[Web of Science][Medline].
38.
Qing, G,
and
Garcia R.
Characterisation of plasma and tissue atrial natriuretic factor during development of moderate high output heart failure in the rat.
Cardiovasc Res
27:
464-470,
1993
39.
Rupp, H,
and
Jacob R.
Response of blood pressure and cardiac myosin polymorphism to swimming training in the spontaneously hypertensive rat.
Can J Physiol Pharmacol
60:
1098-1103,
1982[Web of Science][Medline].
40.
Ruzicka, M,
Keeley FW,
and
Leenen FH.
The renin-angiotensin system and volume overload-induced changes in cardiac collagen and elastin.
Circulation
90:
1989-1996,
1994
41.
Ruzicka, M,
Yuan B,
Harmsen E,
and
Leenen FH.
The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker.
Circulation
87:
921-930,
1993
42.
Schwartz, K,
Lecarpentier Y,
Martin JL,
Lompre AM,
Mercadier JJ,
and
Swynghedauw B.
Myosin isoenzymic distribution correlates with speed of myocardial contraction.
J Mol Cell Cardiol
13:
1071-1075,
1981[Web of Science][Medline].
43.
Sethi, R,
Dhalla KS,
Beamish RE,
and
Dhalla NS.
Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure.
Am J Physiol Heart Circ Physiol
272:
H884-H893,
1997
44.
Sy, AO,
and
Plantholt S.
Congestive heart failure secondary to an arteriovenous fistula from cardiac catheterization and angioplasty.
Cathet Cardiovasc Diagn
23:
136-138,
1991[Web of Science][Medline].
45.
Wang, X,
Dakshinamurti K,
Musat S,
and
Dhalla NS.
Pyridoxal 5'-phosphate is an ATP-receptor antagonist in freshly isolated rat cardiomyocytes.
J Mol Cell Cardiol
31:
1063-1072,
1999[Web of Science][Medline].
46.
Wang, X,
and
Dhalla NS.
Modification of
-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.
Mol Cell Biochem
214:
131-155,
2000[Web of Science][Medline].
47.
Yang, XP,
Sabbah HN,
Liu YH,
Sharov VG,
Mascha EJ,
Alwan I,
and
Carretero OA.
Ventriculographic evaluation in three rat models of cardiac dysfunction.
Am J Physiol Heart Circ Physiol
265:
H1946-H1952,
1993
This article has been cited by other articles:
![]() |
Y. Takewa, E. R. Chemaly, M. Takaki, L. F. Liang, H. Jin, I. Karakikes, C. Morel, Y. Taenaka, E. Tatsumi, and R. J. Hajjar Mechanical work and energetic analysis of eccentric cardiac remodeling in a volume overload heart failure in rats Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H1117 - H1124. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sethi, H. K. Saini, X. Guo, X. Wang, V. Elimban, and N. S. Dhalla Dependence of changes in beta-adrenoceptor signal transduction on type and stage of cardiac hypertrophy J Appl Physiol, March 1, 2007; 102(3): 978 - 984. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Ryan, E. C. Rothstein, I. Aban, J. A. Tallaj, A. Husain, P. A. Lucchesi, and L. J. Dell'Italia Left Ventricular Eccentric Remodeling and Matrix Loss Are Mediated by Bradykinin and Precede Cardiomyocyte Elongation in Rats With Volume Overload J. Am. Coll. Cardiol., February 20, 2007; 49(7): 811 - 821. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. D. Stefano, L. S. Matsubara, and B. B. Matsubara Myocardial dysfunction with increased ventricular compliance in volume overload hypertrophy Eur J Heart Fail, December 1, 2006; 8(8): 784 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. McNicholas-Bevensee, K. B. DeAndrade, W. E. Bradley, L. J. Dell'Italia, P. A. Lucchesi, and M. O. Bevensee Activation of gadolinium-sensitive ion channels in cardiomyocytes in early adaptive stages of volume overload-induced heart failure Cardiovasc Res, November 1, 2006; 72(2): 262 - 270. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-F. Lam, T. E. Peterson, D. M. Richardson, A. J. Croatt, L. V. d'Uscio, K. A. Nath, and Z. S. Katusic Increased blood flow causes coordinated upregulation of arterial eNOS and biosynthesis of tetrahydrobiopterin Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H786 - H793. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, E. Sentex, H. K. Saini, D. Chapman, and N. S. Dhalla Upregulation of {beta}-adrenergic receptors in heart failure due to volume overload Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H151 - H159. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Lam, A. J. Croatt, D. M. Richardson, K. A. Nath, and Z. S. Katusic Heart failure increases protein expression and enzymatic activity of heme oxygenase-1 in the lung Cardiovasc Res, January 1, 2005; 65(1): 203 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Holmes Candidate mechanical stimuli for hypertrophy during volume overload J Appl Physiol, October 1, 2004; 97(4): 1453 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Dent, N. S. Dhalla, and P. S. Tappia Phospholipase C gene expression, protein content, and activities in cardiac hypertrophy and heart failure due to volume overload Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H719 - H727. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, E. Sentex, D. Chapman, and N. S. Dhalla Alterations of adenylyl cyclase and G proteins in aortocaval shunt-induced heart failure Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H118 - H125. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Agarwal and M. S. Segal Intimal Exuberance: Veins in Jeopardy Am. J. Pathol., June 1, 2003; 162(6): 1759 - 1761. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |